Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBaylor Scott & White Casgevy Coverage & Prior Auth…
    Ask Trek AI about this page
    ModifiedBaylor Scott & White Health PlanPolicy 310

    Exagamglogene autotemcel (Casgevy) coverage and prior authorization

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 310 alerts

    Get alerted when Policy 310 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical coverage policy governing prior authorization and medical necessity criteria for exagamglogene autotemcel (Casgevy) for treatment of Sickle Cell Disease (SCD) and Transfusion-dependent β-thalassemia (TDT) for Baylor Scott & White Health Plan members.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyExagamglogene autotemcel (Casgevy) coverage and prior authorization
    Policy CodePolicy 310
    Change TypeMaterial update — added TDT indicationcoding and treatment center attestation changes
    Effective DateJun 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateMay 28, 2027
    Key ActionSubmit prior authorization with documentation showing board-certified hematologist involvement, treatment at an activated authorized treatment center, and fulfillment of universal and indication-specific criteria.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added TDT (transfusion-dependent β-thalassemia) indication (FDA approved) and TDT specific criteria.

    Added CPT code 96409 and updated HCPCS code from J3590 to J3392.

    Updated treatment center criteria to attestation only and reformatted to include 'Universal Criteria' and 'Indication Specific Criteria'.

    Prior Authorization Requiredauthorization requirement
    Age ≥12 yrsminimum eligible age
    One lifetimetreatment limit
    SCD & TDTindications covered
    91.4%TI12 responder rate
    35patients in PES

    Coverage and Medical Necessity Criteria

    Universal Criteria

    Covered when ALL of the following universal criteria are met

    Universal criteria: 1) Exagamglogene is prescribed by or in consultation with a board-certified hematologist; 2) Provider attests member will receive exagamglogene at an activated authorized treatment center; 3) Member is eligible for autologous hematopoietic stem cell transplant (aHSCT); 4) Member does NOT have an available HLA-matched related donor; 5) Member has NOT previously received HSCT, exagamglogene or any other gene therapy, or investigational cellular therapy; 6) Exagamglogene will NOT be used concomitantly with other gene editing therapies; 7) Exagamglogene will be dosed and administered according to FDA-approved labeling; 8) Member does NOT have any exclusionary clinical or laboratory conditions (see list), including but not limited to: WBC <3 × 10^9/L; platelets <50 × 10^9/L not related to hypersplenism; HbF >15%; LVEF <45%; eGFR <60 mL/min/1.73 m^2; advanced liver disease (ALT >3×ULN, direct bilirubin >2.5×ULN, INR >1.5×ULN, cirrhosis, bridging fibrosis, active hepatitis on biopsy); clinically significant active infection; prior/current malignancy or myeloproliferative disorder; significant immunodeficiency; positive HIV, HBV, or HCV testing per policy; intolerance/contraindication to plerixafor or busulfan; prior anaphylaxis to excipients (DMSO, dextran); pregnancy or breastfeeding; history of a significant bleeding disorder.

    All items required

    Sickle Cell Disease (SCD) Coverage

    Covered for SCD when ALL of the following are met

    SCD criteria: 1) Meets Universal Criteria; 2) Age 12 to 50 years inclusive; 3) Karnofsky performance status ≥60% for subjects ≥16 years OR Lansky performance status ≥60% for subjects <16 years; 4) Confirmed SCD genotype by molecular or genetic testing: βS/βS, βS/β0, or βS/β+; 5) History of hydroxyurea failure, intolerance, or documented contraindication to hydroxyurea; 6) Documented history of ≥2 severe vaso-occlusive episodes (sVOE) per year while receiving appropriate supportive care during the previous two years (sVOE defined as: facility visit with administration of analgesics or RBC transfusion; acute chest syndrome with new pulmonary infiltrate; priapism >2 hours requiring facility visit; splenic or hepatic sequestration with ≥2 g/dL drop in hemoglobin); 7) No history of untreated Moyamoya disease or Moyamoya disease that increases bleeding risk.

    All items required

    Transfusion-dependent β-thalassemia (TDT) Coverage

    Covered for TDT when ALL of the following are met

    TDT criteria: 1) Meets Universal Criteria; 2) Age 12 to 35 years inclusive; 3) Karnofsky performance status ≥80% for subjects ≥16 years OR Lansky performance status ≥80% for subjects <16 years; 4) Confirmed TDT genotype by molecular or genetic testing (non-β0/β0 or β0/β0 as specified); 5) Received ≥100 mL/kg/year OR ≥10 units/year of packed RBCs during the previous two years.

    All items required

    Limits

    Lifetime limit: Only one treatment per lifetime is considered medically necessary; repeat administration is considered experimental and investigational.

    Transfusion-dependent β-thalassemia (TDT) efficacy criteria

    Coverage informed by clinical trial outcomes for TDT; primary efficacy endpoint is TI12

    TI12 responder definition: Patient achieves TI12 defined as a weighted average hemoglobin ≥9 g/dL without RBC transfusions for at least 12 consecutive months (evaluated starting 60 days after the last RBC transfusion and within the first 24 months after infusion).Hb >= 9 g/dL

    Primary efficacy endpoint in Trial 2

    Clinical trial results context: Interim analysis in Trial 2: 32/35 (91.4%) evaluable patients achieved TI12; responders remained transfusion-independent with median duration 20.8 months; three non-responders had substantial reductions in transfusion volume and frequency.

    Context for efficacy expectations

    BSWHP considers exagamglogene autotemcel (Casgevy®) for the treatment of all other indications to be experimental and investigational because the effectiveness of this strategy has not been established.

    Due to the wide range of applicable diagnosis codes and potential updates to coding, the policy does not present an exhaustive inclusive list of ICD-10 diagnosis codes; inclusion of a code in the examples does not guarantee reimbursement and members must meet the medical necessity criteria in the policy language.

    BSWHP considers repeat administration of exagamglogene autotemcel (Casgevy®) to be experimental and investigational and therefore not medically necessary, as the effectiveness of administering the therapy more than once has not been established.

    The policy notes that there are ICD-10 entries identified as not covered, but the specific not-covered ICD-10 entries are not listed in this portion of the document.

    Procedure, Drug, and Diagnosis Codes

    CPT Codes (administration)CPT
    96413Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
    96409Chemotherapy administration, intravenous, push technique, single or initial substance/drug
    HCPCS CodesHCPCSCovered
    J3392Injection, exagamglogene autotemcel, per treatment
    ICD-10 Codes (examples provided)ICD-10
    D56.1Beta thalassemia
    D57.00Hb-Ss Disease With Crisis, Unspecified
    D57.01Hb-Ss Disease With Acute Chest Syndrome
    D57.02Hb-Ss Disease With Splenic Sequestration
    D57.03Hb-Ss Disease With Cerebral Vascular Involvement
    D57.04Hb-Ss Disease With Dactylitis
    D57.09Hb-Ss Disease With Crisis With Other Specified Complication
    D57.1Sickle-Cell Disease Without Crisis
    D57.20Sickle-Cell/Hb-C Disease Without Crisis
    D57.211Sickle-Cell/Hb-C Disease With Acute Chest Syndrome
    1–10 of 38
    1/4
    Laboratory and physiologic thresholds
    White blood cell (WBC)WBC <3 × 10^9/L
    PlateletsPlatelet count <50 × 10^9/L (not related to hypersplenism)
    Fetal hemoglobin (HbF)HbF >15%
    Left ventricular ejection fraction (LVEF)LVEF <45% by echocardiogram
    Renal function (eGFR)Estimated GFR <60 mL/min/1.73 m^2
    Liver testsALT >3×ULN; direct bilirubin >2.5×ULN; baseline INR >1.5×ULN
    Most actionable exclusion

    Authorization, Documentation, and Operational Requirements

    Prior Authorization

    Prior authorization required; clinical review

    Prior authorization is required for exagamglogene autotemcel (Casgevy®). All requests will be reviewed by a clinical pharmacist and medical director and must meet the universal criteria and the indication-specific medical necessity criteria in this policy.

    Billing Rule

    Use listed HCPCS/CPT codes on prior authorization; codes do not guarantee payment

    Submit a prior authorization request using the applicable HCPCS and CPT codes listed in the policy; inclusion of a code does not ensure reimbursement — member must meet the policy criteria. Applicable codes include HCPCS J3392 for exagamglogene autotemcel and CPT administration codes 96413 and 96409 for related administration services.

    • HCPCS: J3392 - Injection, exagamglogene autotemcel, per treatment

    Clinical Background and Rationale

    Sickle Cell Disease (SCD) is an autosomal recessive disorder characterized by polymerization of hemoglobin S that leads to red blood cell sickling, chronic hemolytic anemia, recurrent vaso-occlusion with acute painful crises and severe vaso-occlusive episodes, and progressive multi-organ damage. Curative therapy can include hematopoietic stem cell transplant (HSCT) from a matched donor, but matched donors are often unavailable; exagamglogene autotemcel (Casgevy®) is an autologous, CRISPR/Cas9 genome-edited CD34+ hematopoietic stem cell therapy developed to increase fetal hemoglobin and reduce disease manifestations in eligible patients.

    Key Definitions and Terms

    sVOE (severe vaso-occlusive episode)
    Core definitionSevere vaso-occlusive episode (sVOE): an acute event causing significant clinical manifestation meeting any listed criteria
    Acute pain requiring facility visitAcute pain events that required a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs) or RBC transfusions
    Acute chest syndromeNew pulmonary infiltrate with pneumonia-like symptoms, pain, or fever meeting criteria for acute chest syndrome
    PriapismPriapism lasting >2 hours and requiring a visit to a medical facility
    Sequestration eventsSplenic sequestration (enlarged spleen with ≥2 g/dL drop in hemoglobin) or acute hepatic sequestration (sudden liver enlargement with pain and ≥2 g/dL Hb drop)
    Exagamglogene (Casgevy)

    Policy Revision and Updates

    2025-05-12updateLatest

    Added Transfusion-dependent β-thalassemia (TDT) indication and TDT-specific coverage criteria; added CPT code 96409; updated HCPCS code from J3590 to J3392; added ICD-10 code D56.1; updated treatment center criteria to attestation only; other policy formatting and standard language updates.

    2024-06-10new_policy

    Policy created (new policy effective 06/10/2024).

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyExagamglogene autotemcel (Casgevy) coverage and prior authorization
    Policy CodePolicy 310
    Change TypeMaterial update — added TDT indicationcoding and treatment center attestation changes
    Effective DateJun 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateMay 28, 2027
    Key ActionSubmit prior authorization with documentation showing board-certified hematologist involvement, treatment at an activated authorized treatment center, and fulfillment of universal and indication-specific criteria.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaProcedure, Drug, and Diagnosis CodesAuthorization, Documentation, and Operational RequirementsClinical Background and RationaleKey Definitions and TermsPolicy Revision and Updates
    Presence of advanced liver disease defined by any of the above liver thresholds (ALT >3×ULN, direct bilirubin >2.5×ULN, or INR >1.5×ULN)
    TI12 definition threshold
    Definition (weighted average)Weighted average hemoglobin ≥9 g/dL
    Transfusion requirementNo red blood cell transfusions for at least 12 consecutive months
    Assessment windowTI12 evaluated starting 60 days after the last RBC transfusion and within the first 24 months after infusion
    Clinical significanceUsed as the primary efficacy endpoint in Trial 2 for TDT
  1. CPT: 96413 - Chemotherapy administration, IV infusion; up to 1 hour
  2. CPT: 96409 - Chemotherapy administration, IV, push technique
  3. Step Therapy

    Document hydroxyurea failure/intolerance/contraindication for SCD

    For SCD indications, document hydroxyurea failure, intolerance, or a contraindication prior to approval; this is a required element of the SCD indication-specific criteria.

    • Hydroxyurea failure, intolerance, or contraindication must be clearly documented in the record.
    Note
    Documentation Required

    Required documentation to support prior authorization

    Include documentation that the therapy is prescribed by or in consultation with a board-certified hematologist and that the member will receive treatment at an activated authorized treatment center. Also document eligibility for autologous HSCT, absence of an available HLA‑matched related donor, no prior HSCT/gene therapy/investigational cellular therapy, and fulfillment of the appropriate indication-specific criteria (including confirmed genotype and performance status).

    • Prescribing clinician is a board-certified hematologist or consultation is documented.
    • Attestation that treatment will occur at an activated authorized treatment center.
    • Evidence of eligibility for autologous HSCT and lack of an available HLA‑matched related donor.
    • No prior HSCT, exagamglogene or other gene therapy, or investigational cellular therapy.
    • Indication-specific items (e.g., confirmed genotype, age and performance status thresholds).
    Documentation Required

    Provide clinical outcome data (TI12) and related documentation

    When assessing TDT outcomes and continued coverage, provide baseline transfusion requirements, dates of infusion, and hemoglobin measurements to support evaluation of transfusion independence (TI12 defined as weighted average Hb ≥9 g/dL without RBC transfusions for at least 12 consecutive months, evaluated starting 60 days after last RBC transfusion).

    • Baseline transfusion volume and frequency during the 2-year pre‑treatment period.
    • Dates of exagamglogene infusion.
    • Serial hemoglobin values to calculate weighted average Hb and document TI12.
    Denial Risk

    Incomplete criteria or excluded conditions may cause denial

    Requests that do not meet ALL universal criteria or the indication-specific criteria — including the listed laboratory and physiologic cutoffs, genotype and performance status requirements, history exclusions (prior HSCT/gene therapy), or prior therapy requirements — risk denial.

    • Failure to meet lab or physiologic thresholds (e.g., WBC <3×10^9/L, platelets <50×10^9/L, LVEF <45%, eGFR <60 mL/min/1.73 m2) may trigger denial.
    • Requests with prior HSCT, prior gene therapy, investigational cellular therapy, or an available HLA‑matched related donor are not eligible.
    Note

    Coding alone does not guarantee coverage

    Inclusion of an applicable CPT/HCPCS/ICD code on a request or claim does not guarantee coverage or reimbursement; the patient must meet the policy's medical necessity criteria for approval.

    Product typeExagamglogene autotemcel (Casgevy): autologous genome‑edited hematopoietic stem cell (CD34+) gene therapy
    Mechanism of actionCRISPR/Cas9 edits the erythroid‑specific BCL11A enhancer (GATA1 binding site) to reduce BCL11A expression, increasing γ‑globin/HbF production
    Manufacture and administrationCD34+ HSCs collected by apheresis, edited ex vivo, cryopreserved, shipped, thawed, and infused following myeloablative conditioning
    TI12 — Transfusion independence (12 months)
    TI12 (definition)Maintaining a weighted average hemoglobin ≥9 g/dL without RBC transfusions for at least 12 consecutive months
    Evaluation timingAssessment begins 60 days after the last RBC transfusion and may occur any time within the first 24 months after infusion
    Use in trialsPrimary efficacy endpoint in Trial 2 (TDT); interim analysis used TI12 to define responders